NASDAQ:NEO - NeoGenomics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.92 +0.45 (+3.34 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$13.47
Today's Range$13.3591 - $14.04
52-Week Range$7.08 - $14.04
Volume770,493 shs
Average Volume410,671 shs
Market Capitalization$1.08 billion
P/E Ratio232.00
Dividend YieldN/A
NeoGenomics logoNeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Testing laboratories


Debt-to-Equity Ratio0.53
Current Ratio2.03
Quick Ratio1.85


Trailing P/E Ratio232.00
Forward P/E Ratio126.55
P/E Growth6.38

Sales & Book Value

Annual Sales$258.61 million
Price / Sales4.34
Cash Flow$0.4963 per share
Price / Cash28.05
Book Value$2.15 per share
Price / Book6.47


EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins-0.86%
Return on Equity3.19%
Return on Assets1.58%


Outstanding Shares80,620,000

NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Tuesday, May, 1st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The medical research company had revenue of $63.40 million for the quarter, compared to analyst estimates of $62.31 million. NeoGenomics had a negative net margin of 0.86% and a positive return on equity of 3.19%. NeoGenomics's revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 EPS. View NeoGenomics' Earnings History.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for NeoGenomics.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided EPS guidance of $0.15-$0.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.17. The company issued revenue guidance of $260-$272 million, compared to the consensus revenue estimate of $266.42 million.

What price target have analysts set for NEO?

7 equities research analysts have issued twelve-month price targets for NeoGenomics' stock. Their forecasts range from $9.00 to $24.00. On average, they anticipate NeoGenomics' stock price to reach $17.8571 in the next year. View Analyst Ratings for NeoGenomics.

What are Wall Street analysts saying about NeoGenomics stock?

Here are some recent quotes from research analysts about NeoGenomics stock:
  • 1. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)
  • 2. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (3/1/2018)

Who are some of NeoGenomics' key competitors?

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
  • Mr. Steven C. Jones, Exec. VP & Director (Age 55)
  • Dr. Maher Albitar, Chief Medical Officer and Director of R&D (Age 63)
  • Dr. Steven G. Brodie, VP of Operations (Age 57)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)

Has NeoGenomics been receiving favorable news coverage?

News articles about NEO stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. NeoGenomics earned a news sentiment score of 0.04 on Accern's scale. They also gave media coverage about the medical research company an impact score of 45.51 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Light Asset Management LLC (5.90%), BlackRock Inc. (4.92%), Russell Investments Group Ltd. (3.32%), Artisan Partners Limited Partnership (2.68%), Granite Investment Partners LLC (2.11%) and Franklin Resources Inc. (1.93%). Company insiders that own NeoGenomics stock include Alison L Hannah, Jennifer Balliet, Maher Albitar, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.

Which major investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Artisan Partners Limited Partnership, Penn Capital Management Co. Inc., Blair William & Co. IL, C WorldWide Group Holding A S, New York State Common Retirement Fund, Atlantic Trust Group LLC and Allianz Asset Management GmbH. Company insiders that have sold NeoGenomics company stock in the last year include Jennifer Balliet, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.

Which major investors are buying NeoGenomics stock?

NEO stock was acquired by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Franklin Resources Inc., Gabelli Funds LLC, RMB Capital Management LLC, Gamco Investors INC. ET AL, Citadel Advisors LLC, Trexquant Investment LP and Cortina Asset Management LLC. View Insider Buying and Selling for NeoGenomics.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $13.92.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $1.08 billion and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]

MarketBeat Community Rating for NeoGenomics (NEO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  235 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.